28 Jan January 2014: Top Physicians Join Medical Advisory Board
Capture Vascular announced today it has formed a Medical Advisory Board to assist the Company with all facets of developing and using its proprietary thrombectomy technology. Several of the preeminent thought leaders in interventional cardiology have joined as advisors: Dr. Gary Ansel, Dr. Ken Rosenfield and Dr. Jeffrey Chambers.
Dr. Ansel is an internationally renowned interventional expert, both in peripheral vascular and cardiovascular procedures. He serves as an invited faculty member at many of the largest cardiovascular conferences and medical meetings all over the world. Dr. Ansel has been appointed Associate Medical Director of the OhioHealth Research and Innovation Institute in Columbus, Ohio, and serves on the OhioHealth Research Industry Council. He is a primary investigator, both locally and nationally, on numerous research trials, enabling him to provide cutting-edge technology and the best patient care available to those suffering with peripheral and cardiovascular disease.
Currently, he serves as the Director for the Center for Critical Limb Care at Riverside Methodist Hospital in Columbus, Ohio, and as Assistant Clinical Professor of Medicine in the Department of Internal Medicine at the University of Toledo Medical Center in Toledo, Ohio. Dr. Ansel is a founding board member of the Vascular InterVentional Advances Conference (VIVA), a non-profit organization dedicated to the education and research of vascular disease. He received his medical degree from The Ohio State University College of Medicine where he also completed a postgraduate research fellowship in Cardiology. He completed his residency and internship at the Medical University of Toledo and received his post-fellowship training in Peripheral Vascular Intervention at the Ochsner Clinic in New Orleans.
Dr. Rosenfield is the Section Head for Vascular Medicine and Intervention and Chairs the Acute Myocardial Infarction (STEMI) Committee for the cardiac cath lab at Massachusetts General Hospital in Boston. He specializes in complex cardiac and vascular interventions and has spearheaded the development of less-invasive therapies for patients with coronary and vascular disease, both at MGH and nationally, including treatment of carotid, kidney, and leg artery narrowing using stents and other novel devices.
Dr. Rosenfield has played a leading role in clinical trials investigating the utility of renal, carotid, and lower extremity revascularization, intravascular ultrasound, excimer laser angioplasty, thrombolytic therapy, and other technologies for use in cardiovascular disease. He has numerous scientific publications to his credit and is a frequent contributor in the form of book chapters and review articles.
He has played a prominent role in establishing guidelines and practice standards in treatment of peripheral carotid, renal, and coronary artery disease. He regularly interfaces with the FDA, representing the cardiovascular community. He received his B.A. from Dartmouth College, his medical degree from the University of Massachusetts, and performed his residency training at Kaiser San Francisco. In addition, he did a cardiology fellowship at New England Medical Center, followed by an interventional cardiology fellowship at St. Elizabeth’s Medical Center of Boston.
Dr. Chambers is a national leader in the treatment of coronary and vascular interventions, frequently an invited faculty member at the top medical conferences worldwide to lecture and present research data. He currently serves as the Director of the Lipid Clinic at Metropolitan Heart and Vascular Institute, where he has practiced since 1995. His professional interests include coronary artery disease and cardiovascular research. He is a primary investigator for local and national trials, most recently leading the pivotal trial of the Diamondback coronary atherectomy system that Cardiovascular Systems Inc. received FDA clearance for in October 2013.
Dr. Chambers received his medical degree from Wayne State University, and completed all of his training at the University of Minnesota, including an Internal Medicine Internship and Residency, a Cardiovascular Diseases Fellowship, and an Interventional Cardiology Fellowship.